Treatment of Acute Lymphoblastic Leukemia with an RGel/BLyS Fusion Toxin

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2012 Mar 1

PMID 22373785

Citations 10

Authors

R Parameswaran

M Yu

M-A Lyu

M Lim

M G Rosenblum

J Groffen

N Heisterkamp

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children and a major cause of mortality from hematopoietic malignancies in adults. A substantial number of patients become drug resistant during chemotherapy, necessitating the development of alternative modes of treatment. rGel (recombinant Gelonin)/BlyS (B-lymphocyte stimulator) is a toxin-cytokine fusion protein used for selective killing of malignant B-cells expressing receptors for B-cell-activating factor (BAFF/BLyS) by receptor-targeted delivery of the toxin, Gelonin. Here, we demonstrate that rGel/BLyS binds to ALL cells expressing BAFF receptor (BAFF-R) and upon internalization, it induces apoptosis of these cells and causes downregulation of survival genes even in the presence of stromal protection. Using an immunodeficient transplant model for human ALL, we show that rGel/BLyS prolongs survival of both Philadelphia chromosome-positive and negative ALL-bearing mice. Furthermore, we used AMD3100, a CXCR4 antagonist, to mobilize the leukemic cells protected in the bone marrow (BM) microenvironment and the combination with rGel/BLyS resulted in a significant reduction of the tumor load in the BM and complete eradication of ALL cells from the circulation. Thus, a combination treatment with the B-cell-specific fusion toxin rGel/BLyS and the mobilizing agent AMD3100 could be an effective alternative approach to chemotherapy for the treatment of primary and relapsed ALL.

Citing Articles

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.

Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.

Tarighat S, Fei F, Joo E, Abdel-Azim H, Yang L, Geng H Int J Mol Sci. 2021; 22(22).

PMID: 34830047 PMC: 8624256. DOI: 10.3390/ijms222212167.

Targeting chemokines for acute lymphoblastic leukemia therapy.

Hong Z, Wei Z, Xie T, Fu L, Sun J, Zhou F J Hematol Oncol. 2021; 14(1):48.

PMID: 33743810 PMC: 7981899. DOI: 10.1186/s13045-021-01060-y.

BAFF/APRIL System Is Functional in B-Cell Acute Lymphoblastic Leukemia in a Disease Subtype Manner.

Sevdali E, Katsantoni E, Smulski C, Moschovi M, Palassopoulou M, Kolokotsa E Front Oncol. 2019; 9:594.

PMID: 31380267 PMC: 6657364. DOI: 10.3389/fonc.2019.00594.

Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Vicioso Y, Gram H, Beck R, Asthana A, Zhang K, Wong D Cancer Immunol Res. 2019; 7(7):1106-1119.

PMID: 31138521 PMC: 6606383. DOI: 10.1158/2326-6066.CIR-19-0058.

References

Bradstock K, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb D . Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia. 2000; 14(5):882-8. DOI: 10.1038/sj.leu.2401729. View

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N . Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011; 25(8):1314-23. PMC: 3135709. DOI: 10.1038/leu.2011.76. View

Geay J, Buet D, Zhang Y, Foudi A, Jarrier P, Berthebaud M . p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res. 2005; 65(7):2676-83. DOI: 10.1158/0008-5472.CAN-04-2152. View

Rennert P, Schneider P, Cachero T, Thompson J, Trabach L, Hertig S . A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000; 192(11):1677-84. PMC: 2193103. DOI: 10.1084/jem.192.11.1677. View

Mihalcik S, Tschumper R, Jelinek D . Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. Cell Cycle. 2010; 9(24):4884-92. PMC: 3047811. DOI: 10.4161/cc.9.24.14156. View

Reiter A, Schrappe M, Ludwig W, Hiddemann W, Sauter S, Henze G . Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994; 84(9):3122-33. View

De Clercq E . Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol. 2000; 57(5):833-9. View

Parameswaran R, Muschen M, Kim Y, Groffen J, Heisterkamp N . A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res. 2010; 70(11):4346-56. PMC: 2880197. DOI: 10.1158/0008-5472.CAN-10-0300. View

Graf Einsiedel H, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G . Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol. 2005; 23(31):7942-50. DOI: 10.1200/JCO.2005.01.1031. View

10.

Rosenblum M, Cheung L, Liu Y, Marks 3rd J . Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res. 2003; 63(14):3995-4002. View

11.

Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S . Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 2001; 194(11):1691-7. PMC: 2193534. DOI: 10.1084/jem.194.11.1691. View

12.

Maia S, Pelletier M, Ding J, Hsu Y, Sallan S, Rao S . Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One. 2011; 6(6):e20787. PMC: 3110793. DOI: 10.1371/journal.pone.0020787. View

13.

Lyu M, Rai D, Ahn K, Sung B, Cheung L, Marks J . The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia. 2010; 12(5):366-75. PMC: 2864474. DOI: 10.1593/neo.91960. View

14.

Tracey L, Perez-Rosado A, Artiga M, Camacho F, Rodriguez A, Martinez N . Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005; 206(2):123-34. DOI: 10.1002/path.1768. View

15.

Wen X, Lyu M, Zhang R, Lu W, Huang Q, Liang D . Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma. Mol Imaging Biol. 2010; 13(4):721-9. PMC: 6279425. DOI: 10.1007/s11307-010-0391-0. View

16.

Gross J, Johnston J, Mudri S, Enselman R, Dillon S, Madden K . TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000; 404(6781):995-9. DOI: 10.1038/35010115. View

17.

Thompson J, Bixler S, Qian F, Vora K, Scott M, Cachero T . BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001; 293(5537):2108-11. DOI: 10.1126/science.1061965. View

18.

Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, Nel A . The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol. 2000; 165(4):1743-54. DOI: 10.4049/jimmunol.165.4.1743. View

19.

Lyu M, Cheung L, Hittelman W, Marks J, Aguiar R, Rosenblum M . The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther. 2007; 6(2):460-70. DOI: 10.1158/1535-7163.MCT-06-0254. View

20.

Weisberg E, Azab A, Manley P, Kung A, Christie A, Bronson R . Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2011; 26(5):985-90. PMC: 4124489. DOI: 10.1038/leu.2011.360. View